Literature DB >> 28734007

Real-world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies.

Andreas D Meid1, Sarah Mächler1, Walter E Haefeli1, Gerd Mikus1.   

Abstract

Entities:  

Keywords:  DOAC; Pharmacoepidemiology; atrial fibrillation; myocardial infarction; oral anticoagulants

Mesh：

Substances：

Year:  2017        PMID： 28734007      PMCID： PMC5595975          DOI： 10.1111/bcp.13348

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  34 in total

1.  New-user designs with conditional propensity scores: a unified complement to the traditional active comparator new-user approach.

Authors:  Joshua J Gagne
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-02-21       Impact factor: 2.890

2.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld
Journal:  Eur J Cardiothorac Surg       Date:  2016-09-23       Impact factor: 4.191

3.  Performance of time-dependent propensity scores: a pharmacoepidemiology case study.

Authors:  Wayne A Ray; Qi Liu; Bryan E Shepherd
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-11-18       Impact factor: 2.890

4.  Multiple imputation using chained equations: Issues and guidance for practice.

Authors:  Ian R White; Patrick Royston; Angela M Wood
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

5.  Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).

Authors:  Matthew W Sherwood; James D Douketis; Manesh R Patel; Jonathan P Piccini; Anne S Hellkamp; Yuliya Lokhnygina; Alex C Spyropoulos; Graeme J Hankey; Daniel E Singer; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Richard C Becker
Journal:  Circulation       Date:  2014-02-19       Impact factor: 29.690

6.  Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.

Authors:  Torben Bjerregaard Larsen; Lars Hvilsted Rasmussen; Anders Gorst-Rasmussen; Flemming Skjøth; Mary Rosenzweig; Deirdre A Lane; Gregory Y H Lip
Journal:  Am J Med       Date:  2013-12-19       Impact factor: 4.965

7.  Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.

Authors:  Yi-Hsin Chan; Chi-Tai Kuo; Yung-Hsin Yeh; Shang-Hung Chang; Lung-Sheng Wu; Hsin-Fu Lee; Hui-Tzu Tu; Lai-Chu See
Journal:  J Am Coll Cardiol       Date:  2016-09-27       Impact factor: 24.094

8.  Atrial fibrillation: its prevalence and risk factor profile in the German general population.

Authors:  Renate B Schnabel; Sandra Wilde; Philipp S Wild; Thomas Munzel; Stefan Blankenberg
Journal:  Dtsch Arztebl Int       Date:  2012-04-20       Impact factor: 5.594

9.  European Society of Cardiology Guideline-Adherent Antithrombotic Treatment and Risk of Mortality in Asian Patients with Atrial Fibrillation.

Authors:  Cheng-Hung Li; Chia-Jen Liu; Annie Y Chou; Tze-Fan Chao; Ta-Chuan Tuan; Su-Jung Chen; Kang-Ling Wang; Yenn-Jiang Lin; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Fa-Po Chung; Jo-Nan Liao; Tzeng-Ji Chen; Tsu-Juey Wu; Shih-Ann Chen
Journal:  Sci Rep       Date:  2016-08-08       Impact factor: 4.379

10.  Medication Underuse in Aging Outpatients with Cardiovascular Disease: Prevalence, Determinants, and Outcomes in a Prospective Cohort Study.

Authors:  Andreas D Meid; Renate Quinzler; Julia Freigofas; Kai-Uwe Saum; Ben Schöttker; Bernd Holleczek; Dirk Heider; Hans-Helmut König; Hermann Brenner; Walter E Haefeli
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240
View more
  1 in total

1.  Real-world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies.

Authors:  Andreas D Meid; Sarah Mächler; Walter E Haefeli; Gerd Mikus
Journal:  Br J Clin Pharmacol       Date:  2017-07-21       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.